Recently, JumpCan Pharmaceutical received the Drug Registration Certificates issued by the National Medical Products Administration (NMPA) for Compound Polyethylene Glycol (3350) Electrolyte Powder in two specifications (6.9g/bag and 13.9g/bag). This new addition further enriches the company's digestive disease product portfolio and marks another R&D achievement following the acceptance of the marketing application for the Class 1.1 innovative traditional Chinese medicine drug Xiao'er Biantong Granules earlier this month, demonstrating continuous momentum in innovation.

 

Compound Polyethylene Glycol (3350) Electrolyte Powder is indicated for the treatment of chronic constipation and fecal impaction. Polyethylene glycol 3350 exerts a laxative effect through its osmotic action in the intestines. The product is classified as a Chemical Drug Category 3 and has been deemed to have passed the consistency evaluation for generic drug quality and efficacy. With a chocolate flavor, it offers improved palatability.

 

 

JumpCan Pharmaceutical has deep expertise in the digestive disease area, having developed several branded products such as Rabeprazole Sodium Enteric Capsules (Jinuo), Jianwei Xiaoshi Oral Liquid, and Ganhai Weikang Capsules. The company was also the first in China to gain approval for a new-generation bowel cleanser, Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution (Chuanbeiqing), providing a new treatment option for bowel preparation. Aligned with its medium- to long-term development strategy and market demands, the company not only focuses on independent innovation but also drives external expansion through business development initiatives. Previous collaborations include an innovative targeted digestive protease inhibitor with Newsoara Biopharma, and in 2024, the company signed a partnership for a Class 1 new drug in the digestive field. Through continuous efforts to build its digestive product pipeline, JumpCan Pharmaceutical is committed to providing patients with diverse treatment options.

 

 

Guided by the R&D philosophy of "Leading the Frontier, Innovating Fine Products" and the vision of "Build a joyful and vibrant life together", JumpCan Pharmaceutical will continue to prioritize patient needs, innovate and develop more clinically valuable products, and advance industrialization, commercialization, and globalization. By enhancing medication accessibility and driving high-quality, sustainable growth through scientific innovation, the company fulfills its social responsibilities as a listed enterprise and contributes to the Healthy China strategy.